GYKI 52466 dihydrochloride

Pricing Availability   Qty
Description: Selective non-competitive AMPA antagonist
Chemical Name: 4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine dihydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (18)
Reviews (1)
Literature (5)

Biological Activity for GYKI 52466 dihydrochloride

GYKI 52466 dihydrochloride is a selective noncompetitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >50 μM for AMPA-, kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells.

Compound Libraries for GYKI 52466 dihydrochloride

GYKI 52466 dihydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for GYKI 52466 dihydrochloride

M. Wt 366.24
Formula C17H15N3O2.2HCl
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 2319722-40-0
PubChem ID 10042240
InChI Key RUBSCPARMVJNKX-UHFFFAOYSA-N
Smiles Cl.Cl.CC1=NN=C(C2=CC=C(N)C=C2)C2=C(C1)C=C1OCOC1=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for GYKI 52466 dihydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 16.49 50
water 3.3 10

Preparing Stock Solutions for GYKI 52466 dihydrochloride

The following data is based on the product molecular weight 366.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 5.46 mL 27.3 mL 54.61 mL
2.5 mM 1.09 mL 5.46 mL 10.92 mL
5 mM 0.55 mL 2.73 mL 5.46 mL
25 mM 0.11 mL 0.55 mL 1.09 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for GYKI 52466 dihydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for GYKI 52466 dihydrochloride

References are publications that support the biological activity of the product.

Donevan and Rogawsk (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses. Neuron 10 51 PMID: 7678966

Paternain et al (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 185 PMID: 7826635

Rzeski et al (2001) Glutamate antagonists limit tumor growth. Proc.Natl.Acad.Sci.USA 98 6372 PMID: 11331750

Szabados et al (2001) Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res.Bull. 55 387 PMID: 11489346

Tarnawa et al (1989) Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur.J.Pharmacol. 167 193 PMID: 2574112


If you know of a relevant reference for GYKI 52466 dihydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Antagonists

Keywords: GYKI 52466 dihydrochloride, GYKI 52466 dihydrochloride supplier, Selective, non-competitive, AMPA, antagonists, Glutamate, Receptors, iGlur, Ionotropic, GYKI52466, dihydrochloride, 102771-26-6, 1454, Tocris Bioscience

18 Citations for GYKI 52466 dihydrochloride

Citations are publications that use Tocris products. Selected citations for GYKI 52466 dihydrochloride include:

Bao et al (2016) Lentinan produces a robust antidepressant-like effect via enhancing the prefrontal Dectin-1/AMPA receptor signaling pathway Behavioural Brain Research 317 263 PMID: 27693847

Du et al (2008) The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 28 68 PMID: 18171924

Avshalumov et al (2008) AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not DA axons: one source of a retrograde signal that can inhibit DA release. J Neurophysiol 100 1590 PMID: 18632893

Lin et al (2008) Integrin regulation of cytoplasmic calcium in excitatory neurons depends upon glutamate receptors and release from intracellular stores. J Pharmacol Exp Ther 37 770 PMID: 18289871

Bao et al (2016) The Prefrontal Dectin-1/AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-β-Glucan from Maitake. Sci Rep 6 28395 PMID: 27329257

Huang et al (2004) Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. J Neurosci 24 4551 PMID: 15140926

Bretin et al (2017) Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One 12 e0184429 PMID: 28886144

Vielma et al (2014) Nitric oxide modulates the temporal properties of the glutamate response in type 4 OFF bipolar cells. PLoS One 9 e114330 PMID: 25463389

Gerstner et al (2005) Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res 57 771 PMID: 15774829

Fernandes et al (2014) In vitro ischemia triggers a transcriptional response to down-regulate synaptic proteins in hippocampal neurons. PLoS One 9 e99958 PMID: 24960035

Li et al (2016) 3'-Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. Int J Neuropsychopharmacol 19 PMID: 26443809

Kopach et al (2011) Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 152 912 PMID: 21282008

Santos et al (2009) Transmission efficacy and plasticity in glutamatergic synapses formed by excitatory interneurons of the substantia gelatinosa in the rat spinal cord. PLoS One 4 e8047 PMID: 19956641

Fritsch et al (2009) Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. Neuroscience 163 415 PMID: 19540312

Lebrun-Julien et al (2009) Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci 29 5536 PMID: 19403821

Farley et al (2010) Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 13 1207 PMID: 20059803

Park et al (2009) Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain. Mol Pain 4 67 PMID: 19116032

Lobb et al (2010) A dynamic role for GABA receptors on the firing pattern of midbrain DArgic neurons. J Neurophysiol 104 403 PMID: 20445035


Do you know of a great paper that uses GYKI 52466 dihydrochloride from Tocris? Please let us know.

Reviews for GYKI 52466 dihydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used GYKI 52466 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Effective inhibitor of AMPA receptor calcium influx in neurons.
By Karthik Krishnamurthy on 11/15/2021
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Cultured rat motor neurons

Preincubated 40 micromolar of GYKI 52466 for 10 minutes. The image shows the peak fluorescence intensity of fura2-am up on AMPA stimulation. GYKI 52466 efficiently inhibits AMPA receptor-mediated calcium influx.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.